An FDA advisory panel backed Grail’s Galleri multi-cancer early detection blood test, concluding the benefits outweigh risks for patients meeting the proposed indication criteria. The panel voted 10 to 0 on safety and 6 to 4 on effectiveness, with the overall risk-benefit assessment landing 7 to 2. The endorsement follows a large Nature Medicine study reporting that Galleri detected cancer signals in 287 people (about 60% later diagnosed) among more than 35,000 participants, and predicted the tissue of origin in roughly 91% of cases. Panel members still grappled with effectiveness versus harm tradeoffs. The FDA is not required to follow advisory recommendations, but such votes often shape the agency’s review trajectory. Clinically, the move would be the first FDA-authorized multi-cancer early detection blood test of its kind if regulators align. For biotech, the decision is a direct signal that the early-detection category is nearing commercialization milestones—while also demonstrating regulators’ insistence on hard outcomes beyond biomarker performance.